Study #ALLIANCEA081105
ALLIANCE A081105 - Randomized Study of Erlotinib vs Observation in Patients with completely resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small cell lung cancer (NSCLC)
MD Anderson Study Status
Not Accepting
Treatment Agent
Erlotinib Hydrochloride
Description
This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery (resected). Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Study phase:
Phase III
Physician name:
Don Gibbons
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-740-0241
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.